insurance changes to glp-1 drugs Weight Loss Drug Coverage | Medicare Prescriptions | Ozempic | Wegovy GLP-1 insurance change impacts millions

Adverse event categories were drawn from prior literature, clinical knowledge, and a drug side-effect database, covering a wide range of symptoms from gastrointestinal to mental health issues

tuberculosis Mycobacterium tuberculosis FSP1 ferroptosis suppressor protein 1 AIFM2 apoptosis-inducing factor mitochondria-associated 2 NADPH nicotinamide adenine dinucleotide phosphate ESCRT-III endosomal sorting complex required for transport III DHODH dihydroorotate dehydrogenase CoQ10 coenzyme Q10 CoQ coenzyme Q CoQH coenzyme QH 2 BH 4 tetrahydrobiopterin GTP guanosine triphosphate GCH1 GTP cyclohydrolase-1 MBOAT1/MBOAT2 membrane-bound O-acyltransferase domain-containing 1/2 RBMS1 RNA binding motif single-stranded interacting protein 1 HIF-1 hypoxia inducible factor 1 subunit alpha SLC1A1 solute carrier family 1 member 1 LDHA lactate dehydrogenase A N6F11 N6-furfuryl adenine 11 HMGB1 high mobility group box 1 SEC24B SEC24 homolog B HBx hepatitis B virus X protein HAV hepatitis A virus HCV hepatitis C virus HCC hepatocellular carcinoma PRMT9 protein arginine methyltransferase 9 HSPA8 heat shock protein family A member 8 HSCs hepatic stellate cells TFRC transferrin receptor LF liver fibrosis HBsAg hepatitis B virus surface antigen TRIM37 tripartite motif containing 37 HIV human immunodeficiency virus LIP lipase FTH1 ferritin heavy chain mPMs mouse primary microglia HAND HIV-associated neurocognitive disorders METH methamphetamine CNS central nervous system NRF2 NFE2 like bZIP transcription factor 2 MERS-CoV middle east respiratory syndrome coronavirus MARCHF1 membrane associated RING-CH-Type Finger 1 NCOA4 nuclear receptor coactivator 4 FLU A influenza A virus FLU B influenza B virus hNEPCs human nasal epithelial progenitor cells KEAP1 Kelch-like ECH-associated protein 1 TRIM46 tripartite motif containing 46 TAX1BP1 Tax1 binding protein 1 SQSTM1/p62 sequestosome 1 SIV swine influenza virus HSV-1/2 herpes simplex types 1 and 2 VZV varicella zoster virus HHV-6/7/8 human herpesviruses 6/7/8 NPC nasopharyngeal carcinoma TNFR1 tumor necrosis factor receptor 1 Cox4i2 cytochrome c oxidase subunit 4I2 MAPK mitogen-activated protein kinase NDV Newcastle disease virus HAdV-7 human adenovirus type 7 EV-A71 enterovirus A71 PRKN E3 ubiquitin ligase parkin YAP Yes-associated protein Lys90 Lysine 90 LCL lymphoblastoid cell lines M-CoV murine coronavirus CVB3 coxsackievirus B3 DENV dengue virus Fer-1 ferrostatin-1 DFO deferoxamine BQR brequinar PEDV porcine epidemic diarrhea virus ASFV African swine fever virus HO-1 heme oxygenase-1 BCG Bacillus Calmette-Gurin RNS reactive nitrogen species AA-PE arachidonic acid-phosphatidylethanolamines 15-HOO-AA-PE 15-hydroperoxy-arachidonic acid-phosphatidylethanolamines pLoxA lipoxygenase HBE human bronchial epithelial CMA Chaperone-mediated autophagy NO nitric oxide MRSA Methicillin-resistant strains S

Injectable vitamin B12 is a common treatment given to horses

Regulatory Status and FDA Approval Timeline Current FDA Status (as of June 2026) The FDA has not approved retatrutide for any indication as of June 2026

*Check with your healthcare practitioner if you are nursing, pregnant, are under 18, or following a doctor-prescribed protocol